Article
Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG.
mAbs - 1 Jan 2000
Rose Rebecca J, van Berkel Patrick H C, van den Bremer Ewald T J, Labrijn Aran F, Vink Tom, Schuurman Janine, Heck Albert J R, Parren Paul W H I
Abstract excerpt
Antibody engineering is increasingly being used to influence the properties of monoclonal antibodies to improve their biotherapeutic potential. One important aspect of this is the modulation of glycosylation as a strategy to improve efficacy. Here, we describe mutations of Y407 in the CH3 domain of IgG1 and IgG4 that significantly increase sialylation, galactosylation, and branching of the N-linked glycans in the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.